Merck & Co and Avecia have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck Sharp & Dohme or MSD). Avecia Biologics is a contract manufacturing organisation with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.
John McCubbins, senior vice president of biologics and therapeutic protein operations at manufacturing division for Merck, said: “At Merck we continue to execute on our strategy of expanding our biopharmaceutical expertise and manufacturing capacity. This transaction follows an initial strategic development and supply relationship with Avecia Biologics and will provide us with an operational facility staffed by an experienced workforce that is highly skilled in a broad portfolio of bioprocess systems.”
Under the terms of the agreement, Merck will acquire Avecia Biologics and all its assets, including all the company’s process development and scale-up, manufacturing, quality and business support operations located in Billingham, UK. In addition to honoring all Avecia Biologics contractual commitments, Merck plans to engage in discussions with individual customers relating to their specific ongoing and future biological process development and manufacturing needs after the transaction is closed.
Steve Bagshaw, president of Avecia Biologics, said: “Over the past ten years, Avecia Biologics has built and established an enviable reputation for bioprocess development and timely delivery of quality biopharmaceutical ingredients for our customers. This acquisition recognises these successes and now provides the exciting opportunity to focus on advancing Merck’s broad early and mid-stage portfolio of biologic candidates.”
Closing of the transaction is subject to regulatory approval, as well as other customary closing conditions. The Oligomedicines Business of the Avecia group based in the US does not form part of this transaction.